Our lead program is development of a transformative treatment for early onset of Diabetic Retinopathy/Diabetic Macular Edema.
intervention
About Us
We are a preclinical, privately held company pioneering novel therapies for diseases driven by microvascular injury. We aim to address unmet medical needs and transform patient lives.
Our Science
Our therapeutics are founded on groundbreaking science that identified ceramide-rich platform as a novel target, the root cause of microvascular injury and disease for diverse organ types.